207 related articles for article (PubMed ID: 37868989)
1. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma.
Luo W; Hoang H; Liao Y; Pan J; Ayello J; Cairo MS
Front Immunol; 2023; 14():1277987. PubMed ID: 37868989
[TBL] [Abstract][Full Text] [Related]
2. Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.
Vormoor B; Knizia HK; Batey MA; Almeida GS; Wilson I; Dildey P; Sharma A; Blair H; Hide IG; Heidenreich O; Vormoor J; Maxwell RJ; Bacon CM
PLoS One; 2014; 9(1):e85128. PubMed ID: 24409320
[TBL] [Abstract][Full Text] [Related]
3. Large-cohort humanized NPI mice reconstituted with CD34
Xu X; Gu H; Li H; Gao S; Shi X; Shen J; Li B; Wang H; Zheng K; Shao Z; Cheng P; Cha Z; Peng S; Nie Y; Li Z; Guo S; Qian B; Jin G
FASEB J; 2022 Apr; 36(4):e22244. PubMed ID: 35262964
[TBL] [Abstract][Full Text] [Related]
4. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.
Liebsch L; Kailayangiri S; Beck L; Altvater B; Koch R; Dierkes C; Hotfilder M; Nagelmann N; Faber C; Kooijman H; Ring J; Vieth V; Rossig C
Br J Cancer; 2013 Aug; 109(3):658-66. PubMed ID: 23839490
[TBL] [Abstract][Full Text] [Related]
5. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
6. Development of a Bioluminescent Human Osteosarcoma Model in Humanized NSG Mice: A Pilot Study.
Ko Y; Jeong YH; Seo JH; Lee JA
In Vivo; 2021; 35(4):2151-2157. PubMed ID: 34182491
[TBL] [Abstract][Full Text] [Related]
7. Metastasis Assessment in Ewing Sarcoma Using Orthotopic Xenografts.
López-Alemany R; Tirado OM
Methods Mol Biol; 2021; 2226():201-213. PubMed ID: 33326104
[TBL] [Abstract][Full Text] [Related]
8. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
Verma B; Wesa A
Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.
Henrich IC; Jain K; Young R; Quick L; Lindsay JM; Park DH; Oliveira AM; Blobel GA; Chou MM
Cancer Res; 2021 Apr; 81(8):2171-2183. PubMed ID: 33558334
[TBL] [Abstract][Full Text] [Related]
11. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
12. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.
Charan M; Dravid P; Cam M; Audino A; Gross AC; Arnold MA; Roberts RD; Cripe TP; Pertsemlidis A; Houghton PJ; Cam H
Int J Cancer; 2020 Jun; 146(11):3184-3195. PubMed ID: 31621900
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
14. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
16. Using Zebrafish Larvae as a Xenotransplantation Model to Study Ewing Sarcoma.
Pascoal S; Grissenberger S; Scheuringer E; Fior R; Ferreira MG; Distel M
Methods Mol Biol; 2021; 2226():243-255. PubMed ID: 33326107
[TBL] [Abstract][Full Text] [Related]
17. Genetically Engineered Mouse Model in Ewing Sarcoma.
Tanaka M; Nakamura T
Methods Mol Biol; 2021; 2226():183-189. PubMed ID: 33326102
[TBL] [Abstract][Full Text] [Related]
18. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
[TBL] [Abstract][Full Text] [Related]
19. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.
Meraz IM; Majidi M; Meng F; Shao R; Ha MJ; Neri S; Fang B; Lin SH; Tinkey PT; Shpall EJ; Morris J; Roth JA
Cancer Immunol Res; 2019 Aug; 7(8):1267-1279. PubMed ID: 31186248
[TBL] [Abstract][Full Text] [Related]
20. Killing the killer: natural killer cells to treat Ewing's sarcoma.
Ahn YO; Weigel B; Verneris MR
Clin Cancer Res; 2010 Aug; 16(15):3819-21. PubMed ID: 20554750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
